146 related articles for article (PubMed ID: 36007560)
1. Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement.
da Costa NF; Santos IA; Fernandes AI; Pinto JF
J Pharm Sci; 2022 Dec; 111(12):3327-3339. PubMed ID: 36007560
[TBL] [Abstract][Full Text] [Related]
2. Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
da Costa NF; Daniels R; Fernandes AI; Pinto JF
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142179
[TBL] [Abstract][Full Text] [Related]
3. In Situ Co-Amorphization of Olanzapine in the Matrix and on the Coat of Pellets.
da Costa NF; Azevedo RF; Lopes JA; Fernandes AI; Pinto JF
Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559080
[TBL] [Abstract][Full Text] [Related]
4. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
6. Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
da Costa NF; Fernandes AI; Pinto JF
Int J Pharm; 2020 Oct; 588():119716. PubMed ID: 32758593
[TBL] [Abstract][Full Text] [Related]
7. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
8. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
9. Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors.
An JH; Lim C; Kiyonga AN; Chung IH; Lee IK; Mo K; Park M; Youn W; Choi WR; Suh YG; Jung K
Pharmaceutics; 2018 Sep; 10(3):. PubMed ID: 30189645
[TBL] [Abstract][Full Text] [Related]
10. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
[TBL] [Abstract][Full Text] [Related]
11. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
12. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Int J Pharm; 2018 Jun; 544(1):172-180. PubMed ID: 29669257
[TBL] [Abstract][Full Text] [Related]
13. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
14. In Situ Salification in Polar Solvents: a Paradigm for Enabling Drug Delivery of Weakly Ionic Drugs as Amorphous Solid Dispersion.
Nair R; Lamare I; Tiwari NK; Ravi PR; Pillai R
AAPS PharmSciTech; 2018 Jan; 19(1):326-337. PubMed ID: 28721630
[TBL] [Abstract][Full Text] [Related]
15. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
16. In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids.
Maher EM; Ali AM; Salem HF; Abdelrahman AA
Drug Deliv; 2016 Oct; 23(8):3088-3100. PubMed ID: 26960680
[TBL] [Abstract][Full Text] [Related]
17. Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability.
Hu D; Chen X; Li D; Zhang H; Duan Y; Huang Y
Int J Pharm; 2023 Mar; 635():122707. PubMed ID: 36764418
[TBL] [Abstract][Full Text] [Related]
18. Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation.
Khan KU; Akhtar N; Minhas MU
AAPS PharmSciTech; 2020 May; 21(5):141. PubMed ID: 32419084
[TBL] [Abstract][Full Text] [Related]
19. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
20. Co-amorphous systems of sinomenine with nonsteroidal anti-inflammatory drugs: A strategy for solubility improvement, sustained release, and drug combination therapy against rheumatoid arthritis.
Chen X; Li D; Zhang H; Duan Y; Huang Y
Int J Pharm; 2021 Sep; 606():120894. PubMed ID: 34280485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
